M

yoKardia (MYOK) announced Monday that its experimental drug mavacamten demonstrated statistically significant improvements in blood flow and aerobic capacity in patients with an inherited form of heart disease in a small, mid-stage clinical trial.

Eight of the 10 patients who completed the study achieved improvement in blood flow to a level where they no longer met the threshold for being diagnosed with their disease — obstructive hypertrophic cardiomyopathy, or HCM.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Pts with HCM that had operation for it got rid of obstruction but continue to have VO2 problem. Who can I talk to about likely taking them as stage 2-3?

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.